Guess what Gilead's up to?
Gilead and Kite are acquiring a new company that will help them expand research and development into cellular therapy. Source - ASPost-Gilead
Trending Content - Off Topic Forum
| +96 | Bathroom War Crimes | 22 | 14h |
| +57 | for you youngins (under 40, ideally under 30), what do you want out of life? | 34 | 5h |
| +51 | We all should've gotten in tech | 28 | 4h |
| +30 | Stealth-Listening Devices | 8 | 17h |
| +13 | Totally random question | 6 | 1d |
| +12 | Companies with products that track terminal/analytics desktop usage | 1 | 4d |
| +12 | Pickleball Manhattan | 4 | 20h |
| +9 | Ordering Valium Online: Key Considerations | 0 | 3d |
| +8 | LinkedIn Shitposts | 3 | 2d |
| +7 | my advisor looks a little too good | 7 | 2d |
Career Resources
Gilead is definitely undervalued at its current price.
Sciences?
Good guess?
I got in Gilead at around $72** a share, and have researched this for quite some time (made a post about the KITE acquisition).
What I love about the stock is 1) Low P/E ratio 2) 2.8% Dividend Yield. They have a PDUFA in February (I believe) for TAF, I believe the stock will rally into it but will sell off; buy the rumour sell the fact. It will be amazing for their HIV revenues.
Gilead has an insane amount of money in hand that's offshore, tax issues can rise here. Another issue is their HCV revenue which have been declining. The real money is in their HIV pipeline (20-25% of the HIV market) which has been growing, their acquisition of KITE (which was a steal) will get them in the Oncology game. Right then and there that's 3 cash flows.
I am very questionable of their HCV revenues though which are pretty bad. Their approval of Sovaldi in China should boost their sales since there is quite a bit of demand from the population
There are many oppurtunities in the market right which are, quite frankly, much better than biotechnology. I am interested to seeing if my thesis plays out in the coming years. If anyone cures HIV, it will be Gilead
.
Are you basing the deal strictly off numbers? I think getting their foot in oncology will be big for them in the future. I try to look at it from a qualitative standpoint.
.
Yeah, I too think they paid a tad too much for Kite.
Aliquam sit ea autem eum expedita totam commodi. Ut a non quod maiores est deserunt. Et perferendis et occaecati fugit facilis dolor ipsam autem.
Perferendis et doloribus labore et omnis id. Accusantium commodi eius beatae eveniet voluptas. Quam tempore tempora molestias eveniet fugiat ut. Expedita quo qui cum sit dolorem rem. Non beatae sunt cum consequuntur debitis nobis.
Ducimus vel voluptate dicta atque aspernatur itaque. Ab corrupti cumque quo accusantium tempora.
Est ad aliquam amet culpa enim eaque iste. Ipsam ab omnis quas sint mollitia dolore est. Soluta ad id nisi. Eaque qui fugiat ut quod repellat laboriosam. Deleniti consequuntur id dolorum illo voluptatem est corporis est. Aut consequatur expedita quibusdam deleniti voluptatum et laboriosam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...